Notably, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the first dedicated kidney outcome trial evaluating canagliflozin in people with type 2 diabetes mellitus and CKD, demonstrated a substantial reduction in the risk of kidney events [46]
Nausea is the most commonly reported symptom, affecting approximately 20-40% of patients during the first few weeks
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
That means feeling like youre hungry when you really arent, blood sugar peaks and valleys, stubborn fat accumulation, especially around your abdomen, and generally feeling tired and sluggish
Improving health and reducing health risks is more than just a number on a scale, Dr